Description: <b>Gossypol</b> is a natural compound found in cottonseed, a byproduct of the cotton industry. It has been studied for its potential anti-cancer properties. Research has shown that gossypol can inhibit the growth of various types of cancer cells, including breast, prostate, lung, and colon cancer.<br>
<br>
Gossypol's anti-cancer effects are thought to be due to its ability to:<br>
<br>
-Inhibit the activity of certain enzymes involved in cancer cell growth and survival<br>
-Induce apoptosis (cell death) in cancer cells<br>
-Inhibit the formation of new blood vessels that feed cancer cells (anti-angiogenesis)<br>
-Modulate the immune system to attack cancer cells<br>
<br>
Some studies have also suggested that gossypol may have synergistic effects when combined with other anti-cancer agents, such as chemotherapy and radiation therapy.<br>
<p><b>Gossypol</b> — a naturally occurring polyphenolic binaphthyl dialdehyde concentrated in the pigment glands of cotton plants (<i>Gossypium</i> spp.), particularly cottonseed. It is a plant-derived small-molecule bioactive compound and toxicant with two atropisomeric enantiomers. The R-(−) enantiomer, commonly termed <b>(−)-gossypol</b> or <b>AT-101</b> when developed as gossypol acetic acid, has substantially greater anticancer activity than the S-(+) enantiomer and has been clinically investigated as an orally administered BH3-mimetic anticancer agent. Gossypol itself is not an approved anticancer drug; R-(−)-gossypol has FDA orphan-drug designation for chronic lymphocytic leukemia but has not received FDA approval for that indication. Cottonseed or crude cotton-derived material should not be considered equivalent to pharmaceutical AT-101 because gossypol content, stereochemistry, binding state, exposure, and toxicity are poorly controlled.</p>
<p><b>Primary mechanisms (ranked):</b></p>
<ol>
<li>BH3-mimetic inhibition of anti-apoptotic BCL-2-family proteins, particularly BCL-2, BCL-XL and MCL-1, releasing pro-apoptotic BAX/BAK signaling and lowering the mitochondrial apoptotic threshold.</li>
<li>Mitochondrial dysfunction and intrinsic apoptosis, including mitochondrial outer-membrane permeabilization, loss of membrane potential, impaired respiration and ATP production, cytochrome-c-associated caspase activation, and apoptotic cell death.</li>
<li>Disruption of BCL-2/Beclin-1 and BCL-XL/Beclin-1 complexes, permitting Beclin-1-dependent autophagy; the contribution of autophagy to tumor-cell death versus survival is context-dependent.</li>
<li>Inhibition of lactate dehydrogenase and other dehydrogenases, producing reduced glycolytic lactate formation and metabolic stress; this is pharmacologically established but appears less central to modern clinical development than BCL-2-family antagonism.</li>
<li>Chemosensitization and radiosensitization through lowering of the apoptotic threshold, particularly in tumors dependent on BCL-2/BCL-XL/MCL-1 survival signaling.</li>
<li>ROS and oxidative-stress modulation (secondary, context-dependent); increased ROS contributes to cytotoxicity in some tumor models, whereas other models demonstrate ROS-independent mitochondrial apoptosis.</li>
<li>Suppression of tumor growth, angiogenic signaling and selected invasion-associated pathways in preclinical models, including reductions in VEGF-related signaling in some systems; these are secondary and tumor-model-dependent effects.</li>
</ol>
<p><b>Bioavailability / PK relevance:</b> Gossypol and AT-101 have been administered orally in human cancer trials. Absorption is relatively slow and highly variable between individuals. In one clinical PK study using AT-101 40 mg twice daily, mean plasma Cmax was approximately 0.66 µg/mL, equivalent to about 1.3 µM, with individual values approximately 0.6–1.8 µM and a mean measured elimination half-life near 3.3 hours during the sampling interval. Other trials using 10–20 mg doses reported peaks of roughly 300–700 ng/mL around 1.5–2.5 hours. Gossypol is strongly protein-reactive/protein-bound and undergoes extensive tissue distribution, making total plasma concentration an imperfect surrogate for pharmacologically available intracellular exposure. Human pharmacokinetic behavior is heterogeneous and no validated therapeutic plasma concentration has been established.</p>
<p><b>In-vitro vs systemic exposure relevance:</b> Clinically achieved total plasma concentrations can reach the low-micromolar range and therefore overlap with some experiments demonstrating BCL-2-family inhibition, mitochondrial disruption and radiosensitization. However, many preclinical experiments use approximately 5–30 µM gossypol, which exceeds typical total human plasma exposure, sometimes substantially. Strong protein binding further reduces free-drug exposure. Mechanistic findings requiring high-micromolar concentrations should therefore be classified as high-concentration preclinical effects rather than assumed clinically achievable mechanisms.</p>
<p><b>Clinical evidence status:</b> Human Phase I and Phase II evidence exists for racemic gossypol and particularly AT-101, including monotherapy and combinations with docetaxel, cisplatin/etoposide, paclitaxel/carboplatin, radiation/temozolomide, and lenalidomide/dexamethasone. Several randomized studies failed to demonstrate significant survival improvement, and multiple development programs were stopped for lack of prespecified efficacy. More recent small studies have shown potentially useful activity in selected settings, including a 10-patient relapsed/refractory multiple-myeloma study and trials in glioblastoma, but these remain exploratory. Overall classification: <b>clinical investigational; Phase I/II human evidence; no established standard-of-care indication and no FDA anticancer approval</b>. Dose-limiting and clinically relevant toxicities have included gastrointestinal toxicity, hepatic enzyme elevation, cytopenias in combination regimens, electrolyte disturbances including hypokalemia, and reproductive toxicity with suppression of spermatogenesis.</p>
<h3>Gossypol Cancer-Relevant Mechanisms</h3>
<table>
<thead>
<tr>
<th>Rank</th>
<th>Pathway / Axis</th>
<th>Cancer Cells</th>
<th>Normal Cells</th>
<th>Primary Effect</th>
<th>Notes / Interpretation</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>BCL-2 / BCL-XL / MCL-1 survival signaling</td>
<td>↓</td>
<td>↓ (context-dependent)</td>
<td>BH3-mimetic displacement of pro-apoptotic BCL-2-family partners</td>
<td>Principal anticancer mechanism of R-(−)-gossypol / AT-101. Tumors dependent on anti-apoptotic BCL-2-family proteins may be preferentially susceptible.</td>
</tr>
<tr>
<td>2</td>
<td>Mitochondrial apoptosis</td>
<td>↑</td>
<td>↑ (dose-dependent)</td>
<td>Mitochondrial permeabilization, membrane-potential loss and caspase-associated apoptosis</td>
<td>Closely linked to BCL-2-family inhibition. Therapeutic selectivity is incomplete and depends on cellular BCL-2-family dependence and exposure.</td>
</tr>
<tr>
<td>3</td>
<td>Mitochondrial bioenergetics</td>
<td>↓</td>
<td>↓ (dose-dependent)</td>
<td>Reduced mitochondrial respiration and ATP production</td>
<td>Demonstrated experimentally with AT-101 and may augment apoptotic stress. High exposure can also impair normal-cell mitochondrial function.</td>
</tr>
<tr>
<td>4</td>
<td>BCL-2 / Beclin-1 autophagy control</td>
<td>↓ BCL-2–Beclin-1 binding<br>↑ autophagy</td>
<td>↔ / ↑ (context-dependent)</td>
<td>Release of Beclin-1 and induction of autophagic signaling</td>
<td>Particularly described in apoptosis-resistant, BCL-2-high prostate cancer. Autophagy may contribute to cell death or cellular adaptation depending on model.</td>
</tr>
<tr>
<td>5</td>
<td>LDH-dependent glycolysis and lactate production</td>
<td>↓</td>
<td>↓ (dose-dependent)</td>
<td>Dehydrogenase inhibition and reduced lactate-forming glycolytic flux</td>
<td>Gossypol is a recognized LDH inhibitor, but this mechanism has received less clinical validation than BH3-mimetic activity.</td>
</tr>
<tr>
<td>6</td>
<td>Chemosensitization</td>
<td>↑</td>
<td>↔ / ↑ toxicity (context-dependent)</td>
<td>Lowers apoptotic threshold to cytotoxic agents</td>
<td>Synergy or enhanced cytotoxicity has been demonstrated with cisplatin, taxanes, etoposide, bortezomib and other agents preclinically. Human combination trials have produced mixed efficacy.</td>
</tr>
<tr>
<td>7</td>
<td>Radiosensitization</td>
<td>↑</td>
<td>↔ / ↑ toxicity (context-dependent)</td>
<td>Enhances radiation-associated tumor-cell killing</td>
<td>Low-micromolar AT-101 concentrations can radiosensitize tumor models, and clinically measured plasma concentrations have overlapped this range in some studies.</td>
</tr>
<tr>
<td>8</td>
<td>Oxidative and mitochondrial ROS stress</td>
<td>↑ (model-dependent)</td>
<td>↑ (high concentration only)</td>
<td>Oxidative stress contributing to apoptosis in selected tumor models</td>
<td>Secondary mechanism. ROS induction is not universal; ROS-independent mitochondrial apoptosis has also been demonstrated.</td>
</tr>
<tr>
<td>9</td>
<td>Angiogenic signaling</td>
<td>↓ (model-dependent)</td>
<td>↓ (context-dependent)</td>
<td>Reduced angiogenic signaling and tumor vascular support</td>
<td>VEGF and related angiogenic markers decrease in selected preclinical models. Evidence is substantially weaker than for BCL-2-family antagonism.</td>
</tr>
<tr>
<td>10</td>
<td>Clinical Translation Constraint</td>
<td>↔</td>
<td>↓ therapeutic margin</td>
<td>Exposure variability, protein binding, toxicity and limited demonstrated efficacy</td>
<td>Oral absorption is variable; many in-vitro studies use concentrations above typical systemic exposure. Reproductive toxicity, gastrointestinal toxicity, hepatic effects, electrolyte abnormalities and hematologic toxicity constrain dosing. Multiple randomized Phase II programs failed to improve major clinical outcomes.</td>
</tr>
</tbody>
</table>